Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
